CN109868306A - A kind of the rapid amplifying kit and amplification method of CYP2C19 gene - Google Patents

A kind of the rapid amplifying kit and amplification method of CYP2C19 gene Download PDF

Info

Publication number
CN109868306A
CN109868306A CN201711267084.5A CN201711267084A CN109868306A CN 109868306 A CN109868306 A CN 109868306A CN 201711267084 A CN201711267084 A CN 201711267084A CN 109868306 A CN109868306 A CN 109868306A
Authority
CN
China
Prior art keywords
cyp2c19
type
amplification
kit
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201711267084.5A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinkaiyuan Honghui (guangzhou) Biotechnology Co Ltd
Original Assignee
Xinkaiyuan Honghui (guangzhou) Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinkaiyuan Honghui (guangzhou) Biotechnology Co Ltd filed Critical Xinkaiyuan Honghui (guangzhou) Biotechnology Co Ltd
Priority to CN201711267084.5A priority Critical patent/CN109868306A/en
Publication of CN109868306A publication Critical patent/CN109868306A/en
Withdrawn legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a kind of rapid amplifying kit of CYP2C19 gene and amplification methods, it wherein include three pairs of amplimers, Taq enzyme, dNTPs and buffer in kit, wherein amplimer is used to expand at least two SNP sites in CYP2C19*2 type, CYP2C19*3 type and CYP2C19*17 type, and each pair of primer respectively corresponds the upstream and downstream region of one of SNP site.The present invention uses the amplification method of multiplex PCR, while expanding multiple important SNP sites of CYP2C19, and can flexible choice amplification according to actual needs Sites Combination, the multi-purpose effect of a box can be played, primer specificity in kit is high, and mismatch rate is low, primer length and TmRationally, amplified production is convenient for detection separation for value design.A plurality of purpose product is once expanded, amplification efficiency is not only substantially increased, reduces amplification cost.

Description

A kind of the rapid amplifying kit and amplification method of CYP2C19 gene
Technical field
The present invention relates to a kind of rapid amplifying kit of CYP2C19 gene and amplification methods, belong to biological field, especially It is field of biological detection.
Background technique
Drug metabolic enzyme plays an important role during drug metabolism in vivo, and activity height directly determines drug effect Intensity and persistence.Cytochrome P450 (CYP450) is the main enzyme of the intracorporal drug metabolism of people, take part in 40%~ The metabolism of 50% marketed drug, active power are an important factor for determining drug metabolic rate.
CYP2C19 enzyme is known as S- mephenytoin -4- hydroxylase, is Cytochrome P450 family (CYP450) most important medicine One of object metabolic enzyme, the gene pleiomorphism of CYP2C19 affect clopidogrel, Omeprazole, dilantin sodium and diazepam etc. and are permitted The metabolism of drug.CYP2C19 enzyme is located in hepatomicrosome, and encoding gene is located at chromosome q24.1-24.3 of the mankind No. 10 Point, wild type are CYP2C19*1/*1 type, have normal enzymatic activity,.But often there is gene mutation in Chinese population, common mutations class Type is CYP2C19*2 type (the 5th exon G681A) and CYP2C19*3 type (the 4th exon G636A).CYP2C19*2 type and The enzymatic activity that CYP2C19*3 type can cause CYP2C19 gene to encode is lost, and the reduced capability of metabolism substrate increases blood concentration Height easily causes accumulation of poisoning in Normal therapeutic dose.Poor metabolizer 99% in Chinese population be CYP2C19*2 type and CYP2C19*3 type allele.Sim in 2006 etc. has found a kind of new CYP2C19 allele C YP2C19*17, has Mutational site is: -806C > T.CYP2C19*17 allele also has higher frequency to occur in crowd, CYP2C19*17 type The enzymatic activity enhancing for then causing CYP2C19 gene to encode, the ability enhancing of metabolism substrate, it is therefore desirable to increase drug dose.
There are many clinical or laboratory testing CYP2C19 gene pleiomorphism method at present, including PCR sequencing PCR, gene chips With fluorescence quantitative PCR method etc..But various detection methods are detected for single mononucleotide polymorphism site (SNP) , detection time is longer and testing cost is higher, but the frequency of mutation in above three mutational site is higher, and individually detection not only consumes When laborious and accuracy rate it is low, it is difficult to provide the qualitative conclusions in site in a short time.It thus can not real-time and accurately give tested Person is accurately metabolized outcome prediction and medication guide.
To sum up, it researches and develops a to this 3 sites CYP2C19 gene C YP2C19*2, CYP2C19*3 and CYP2C19*17 Polymorphism carries out the rapid amplifying box and amplification detection method of qualitative detection, is highly important.
Summary of the invention
In view of the above-mentioned problems existing in the prior art, the purpose of the present invention obtains a kind of rapid amplifying of CYP2C19 gene Kit and amplification method.
One of for achieving the above object, the technology of the rapid amplifying kit for the CYP2C19 gene that the present invention uses Scheme is as follows:
It include three pairs of amplimers, Taq enzyme, dNTPs and buffer in the kit, wherein amplimer is for expanding At least two SNP sites in CYP2C19*2 type, CYP2C19*3 type and CYP2C19*17 type, each pair of primer respectively correspond wherein The upstream and downstream region of one SNP site.Three SNP sites are respectively corresponded comprising three pairs of primers in kit, and when amplification can be same When three SNP sites of amplification or arbitrarily two sites of selection expanded so that kit using more flexible, and three pairs Primer passes through careful design, and the high mispairing of amplification efficiency is low, amplified production easily detect it is easily separated, convenient for further sequencing or detection Work is gone on smoothly.
The amplification template sequence of CYP2C19*2 type is as shown in sequence table SEQ ID NO:1, the amplification mould of CYP2C19*3 type Plate sequence is as shown in sequence table SEQ ID NO:2, the amplification template sequence of CYP2C19*17 type such as sequence table SEQ ID NO:3 institute Show.
The three pairs of primers designed according to three SNP sites, that is to say, that be one by one between every pair of primers and amplified fragments Corresponding, the primer sequence of three pairs of primers is as shown in sequence table SEQ ID NO:4~SEQ ID NO:9, wherein SEQ ID NO:4 It is respectively the upstream and downstream amplimer of CYP2C19*2 type with SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 is respectively The upstream and downstream amplimer of CYP2C19*3 type, SEQ ID NO:8 and SEQ ID NO:9 are respectively the upper and lower of CYP2C19*17 type Swim amplimer.
In multiplexed PCR amplification, the additive amount of every group of amplification template and primer is identical as Standard PCR, adds between every group It measures identical, influencing each other between all primer and template when amplification can be made to be reduced to minimum in this way.
Amplification kit in the present invention is generally using processed DNA sample as amplification template, the general source of sample In people's whole blood or tissue, handling sample, can to reduce immunoglobulin G in blood, hemoglobin and lactoferrin anti-to PCR Answer the interference of system.
Preferably, whole blood sample PCR buffer is additionally provided in this kit, the buffer contains 100mmol/LTris- HCl, 50mmol/L KCl, pH 9.3~9.5.Whole blood sample PCR buffer is a kind of preferred embodiment of the invention, He can use the whole blood PCR reagent of type, the buffer and buffer formulation being not limited in the present invention.
Second object of the present invention is to provide a kind of amplification method using above-mentioned amplification kit, and the method is adopted With the multiplex PCR system of 25 μ L, specifically:
10×PCR buffer 2μL;
Mg2+(25mmol/L)1μL;
dNTPs(25mmol/L)0.6μL;
Taq enzyme (5U/ μ L) 0.3 μ L;
CYP2C19*2 type, CYP2C19*3 type and/or each 2 μ L of CYP2C19*17 pattern plate;
CYP2C19*2 type, CYP2C19*3 type and/or CYP2C19*17 type upstream and downstream primer (10 μm of ol/L) each 1 μ L;Its Middle primer is corresponding with the type of template and quantity,
Aseptic double-distilled water polishing is to 25 μ L.
According to the difference of the amplified band quantity of multiplex PCR, the additional amount of aseptic double-distilled water is adjusted, to guarantee reaction system It is complete.Since the amplification selection of this kit has CYP2C19*2 type and CYP2C19*3 type, CYP2C19*3 type and CYP2C19* Four kinds of 17 types, CYP2C19*2 type and CYP2C19*17 type, CYP2C19*2 type, CYP2C19*3 type and CYP2C19*17 type situations, Therefore it according to the difference of amplification template, needs that the corresponding primer of template is added in system, and adjust the amount of water of whole system.
The multi-PRC reaction condition that this kit is recommended are as follows: 94 DEG C of initial denaturation 5.5min;Then 94 DEG C of denaturation 30s, 58 DEG C Anneal 45s, 72 DEG C of extensions 50s, after 36 recycle, 72 DEG C of extension 5min again.
Augmentation detection is generally carried out using the DNA sample after purification processes in this kit.But further include in this kit Whole blood amplification buffer, convenient for directly expanding collected people's whole blood sample, when amplification, is replaced with whole blood sample buffer Change the PCR buffer in existing PCR system.
Compared with prior art, the present invention uses the amplification method of multiplex PCR, while expanding the multiple important of CYP2C19 SNP site, and can flexible choice amplification according to actual needs Sites Combination, the multi-purpose effect of a box, reagent can be played Primer specificity in box is high, and mismatch rate is low, primer length and TmRationally, amplified production is convenient for detection separation for value design.Once A plurality of purpose product is expanded, amplification efficiency is not only substantially increased, reduces amplification cost.This detection kit can extend It extends in other SNP site detections, there is good promotional value.
Detailed description of the invention
Fig. 1 is pcr amplification product electrophoretogram provided by the invention.
Specific embodiment
Below with reference to rapid amplifying kit and amplification method of the embodiment to CYP2C19 gene provided by the invention make into One step illustrates in detail, completely.The embodiments described below is exemplary, and for explaining only the invention, and should not be understood as Limitation of the present invention.
Experimental method in following embodiments is unless otherwise specified conventional method.Reality as used in the following examples It tests material unless otherwise specified, is that market is commercially available.
Rapid amplifying kit in the present embodiment carries out same for the higher SNP site of three frequencies for CYP2C19 When the multiple PCR reagent kit that expands, it is poly- including the upstream and downstream amplimer and amplification template, Taq DNA of three pairs of SNP sites Synthase, dNTPs and buffer.Taq archaeal dna polymerase is the Ex Taq archaeal dna polymerase of TaKaRa company.Three in the present embodiment A template is respectively CYP2C19*2 type, CYP2C19*3 type and CYP2C19*17 type.
The DNA profiling used in the present embodiment kit is the DNA profiling that treated extracts, for people's whole blood of acquisition Or it for tissue, needs to be handled in advance.It, need to be using for whole blood if sample to be amplified is untreated whole blood sample The buffer of product PCR, wherein containing 100mmol/L Tris-HCl, 50mmol/L KCl, pH 9.3~9.5.
One, amplimer designs
In the present embodiment using multiplex PCR composite amplification CYP2C19*2 type, CYP2C19*3 type and CYP2C19*17 type this Three sites carry out rapid amplifying to above-mentioned site, and specific sequence to be amplified is as follows:
CYP2C19*2 type genotypic sequences recorded in NCBI marked as rs4451645, sequence such as sequence table SEQ ID Shown in NO:1, wherein " R " represents SNP site, indicate that the variation in the site is A/G, specific as follows:
ATACATGGTGCTTGATAAGATCTGAAGATAGGTGAAGAGTAAGCATGTCCATTCATTGTTTAGTTGCCT ATCCATCCATTCATCCATTAATCCTTCCACCCATCCATCCTTTCATTCATGCATTCACCCAACCACCCATCTATCTA CTCATCCCTCCTATGATTCACCGAACAGTTCTTGCATATTCTGTCTGTGCCAGTTATAGAGACAGTGTTTGTCACTC TCACAGTTACACATGAGGAGTAACTTCTCCCT
R
TGTTTGTTATTTTCAGGAAAACGGATTTGTGTGGGAGAGGGCCTGGCCCGCATGGAGCTGTTTTTATTCCTGACCTT CATTTTACAGAACTTTAACCTGAAATCTCTGATTGACCCAAAGGACCTTGACACAACTCCT GTTGTCAATGGATTTGCTTCTGTCCCGCCCTTCTATCAGCTGTGCTTCATTCCTGTCTGAAGAAGCACAGATGGTCT GGCTGCTCCTGTGCTGTCCCTGCAGCTCTCTTTCCTCTGG
CYP2C19*3 type genotypic sequences recorded in NCBI marked as rs17885567, sequence such as sequence table SEQ Shown in ID NO:2, wherein " Y " represents SNP site, indicate that the variation in the site is C or T, specific as follows:
CCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAGAAAAGTAACTACT TCATGCCTTTCTCAGCAGGTAATATAAATTTATTTCCCTTTGTGTTTCAGGGTACAAGATAACTTTTTTGATCAGTT GGAACTTACATGTGCCTTCTCTGCAGTGGTACAGTTACTCTTTGTACATGATCAAGAGCACTGTTCTGAATGCCTGT GTTTTCTCCGCTGGTGATACATCCTCATTATT
Y
GGCCAGATTAGTGGGTTTTGGAGAATTAATCCAATTCTTCCAAATTGAGAAAGCTGAAGTATAGGTTGG TTGAATTCTGCCTCTAGATACACCACTGAGGTACTCAAGAACTCCTCCTGGAAGATAAAACTAATTACATTTTCCTC ACTAGCCATGAGGAAGTTATCTCACTCCAGAACTTCACTGAGTGTCTTCCACATGGTGTCCCTCACCCCCTAGGCTG GGCTTGTAGGATAAAATTATCCTCAAACACAG
CYP2C19*17 type genotypic sequences recorded in NCBI marked as rs3814637, sequence such as sequence table SEQ Shown in ID NO:3, wherein " B " represents SNP site, indicate that the variation in the site is not in base A, specific as follows:
TTGGCTACAGTACTGAATCTTCAAGGCTCAGCCTCCTCATTCCTGAGATGGGTCAATTTTATTGTAAGC AAAGGCAATTGAGAGATTCCAAAGGGATATGAGGTGTGAGAATTCTCTCTAAATGGGGTTAGAATCCCTGTTAAAAA TGACCAGTGAAACATTGTGCAATTGTGTCTTAACATAACTTACTTTTTCTTAATAAGAGAACTGGAAATAACCTCAT TAGGAAATTTAGAACAAATA
B
GATGATATCTTTAAAGAAAATGGCTTTGTGTAAGTATTGTCGTTAGTGATCTAGTAATGTGTATCTTTC TGGTTGTATTTAGACCTTCAACTCAAATGTCAGCTCCCGTTAAGGTCTATACATTGTGGTGGTTTTGTGCTGTGGGT CCATTTAGTGATTTCCCTACCTCCCATCCTCTATTAGATTCACAACTGTTGTTCTGCCCATAATTTCCTATGCTTGC TTTGCATTGTTACATTTTTTTTTGAAAATCAGAAAGCAAAATCAATATAAAGCAGCCATGTCTGGAGGAGACCAGGA GGTCAAGAAGCCTTAGTTTCTCAAGCCCTTAGCACCAAATTCTCTGAGATCAGCTCTTCCTTCAGTTACACTGAGCA TTTCCCCTCTGCAGTGATGGAGAAGGGAGAACTCTTATTTTTTCTCATGAGCATCTCTGGGGCTGTTTTCCTTAGAT AAATAAGTGGTTCTATTTAATGTGAAGCCTGTTTTATGAACAGGATGAATGTGGTATATATTCAGAATAACTAATGT TTGGAAGTTGTTTTGTTTTGCTAAAACAAAGTTTTAGCAAACGATTTTTTTTTTCAAATTTGTGTCTTCTGTTCTCA AAGCATCTCTGATGTAAGAGATAATGCGCCACGATGGGCATCAGAAGACCTCAGCTCAAATCCCAGTTCTGCCAGCT ATGAGCTGTGTGGCACCAACAGGTGTCCTGTTCTCCCAGGGTCTCCCTTTTCCCATTTGAAATATAAAAAATAACAA TTCCTGCCTTCACGTGTTTTTTTAGGGGGTTAAATGGTAAAGGTGTTTATATCTGCTAAGGTAATTTACTTGATATA TGTTTGGTTATTGAAGAT
According to above-mentioned sequence design three to amplimer, primer sequence is specific as follows:
Two, multiplex PCR
The PCR system of 25 μ L is selected, wherein
10×PCR buffer 2μL;
Mg2+(25mmol/L)1μL;
dNTPs(25mmol/L)0.6μL;
Taq enzyme (5U/ μ L) 0.3 μ L;
CYP2C19*2 type, CYP2C19*3 type and each 2 μ L of CYP2C19*17 pattern plate;
CYP2C19*2 type, CYP2C19*3 type and CYP2C19*17 type upstream and downstream primer (10 μm of ol/L) each 1 μ L;
Aseptic double-distilled water polishing is to 25 μ L.
PCR reaction condition: 94 DEG C of initial denaturation 5.5min;Then 94 DEG C of denaturation 30s, 58 DEG C of annealing 45s, 72 DEG C of extension 50s, After 36 circulations, 72 DEG C of extension 5min again.
Three, PCR product is verified
2% agarose gel electrophoresis is selected, for electrophoretogram as shown in Figure 1, band 1 is DNA Marker, band 2 is negative right According to band 3 is amplified production, and electrophoresis result proves that amplification is errorless.
Sequencing will be sent after the recycling of electrophoresis result glue, sequencing result is also consistent with purpose product sequence.
Be it is necessary to described herein finally: above embodiments are served only for making technical solution of the present invention further detailed Ground explanation, should not be understood as limiting the scope of the invention, those skilled in the art's above content according to the present invention The some nonessential modifications and adaptations made all belong to the scope of protection of the present invention.
Sequence table
<110>Xiang Tan intelligence connection technique transfers promote Co., Ltd
<120>the rapid amplifying kit and amplification method of a kind of CYP2C19 gene
<130> 2017
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 511
<212> DNA
<213> Homo sapiens
<220>
<221> gene
<222> (1)..(511)
<223>CYP2C19*2 type genotypic sequences
<400> 1
atacatggtg cttgataaga tctgaagata ggtgaagagt aagcatgtcc attcattgtt 60
tagttgccta tccatccatt catccattaa tccttccacc catccatcct ttcattcatg 120
cattcaccca accacccatc tatctactca tccctcctat gattcaccga acagttcttg 180
catattctgt ctgtgccagt tatagagaca gtgtttgtca ctctcacagt tacacatgag 240
gagtaacttc tccctrtgtt tgttattttc aggaaaacgg atttgtgtgg gagagggcct 300
ggcccgcatg gagctgtttt tattcctgac cttcatttta cagaacttta acctgaaatc 360
tctgattgac ccaaaggacc ttgacacaac tcctgttgtc aatggatttg cttctgtccc 420
gcccttctat cagctgtgct tcattcctgt ctgaagaagc acagatggtc tggctgctcc 480
tgtgctgtcc ctgcagctct ctttcctctg g 511
<210> 2
<211> 511
<212> DNA
<213> Homo sapiens
<220>
<221> gene
<222> (1)..(511)
<223>CYP2C19*3 type genotypic sequences
<400> 2
ccaacccaga gatgtttgac cctcgtcact ttctggatga aggtggaaat tttaagaaaa 60
gtaactactt catgcctttc tcagcaggta atataaattt atttcccttt gtgtttcagg 120
gtacaagata acttttttga tcagttggaa cttacatgtg ccttctctgc agtggtacag 180
ttactctttg tacatgatca agagcactgt tctgaatgcc tgtgttttct ccgctggtga 240
tacatcctca ttattyggcc agattagtgg gttttggaga attaatccaa ttcttccaaa 300
ttgagaaagc tgaagtatag gttggttgaa ttctgcctct agatacacca ctgaggtact 360
caagaactcc tcctggaaga taaaactaat tacattttcc tcactagcca tgaggaagtt 420
atctcactcc agaacttcac tgagtgtctt ccacatggtg tccctcaccc cctaggctgg 480
gcttgtagga taaaattatc ctcaaacaca g 511
<210> 3
<211> 1101
<212> DNA
<213> Homo sapiens
<220>
<221> gene
<222> (1)..(1101)
<223>CYP2C19*17 type genotypic sequences
<400> 3
ttggctacag tactgaatct tcaaggctca gcctcctcat tcctgagatg ggtcaatttt 60
attgtaagca aaggcaattg agagattcca aagggatatg aggtgtgaga attctctcta 120
aatggggtta gaatccctgt taaaaatgac cagtgaaaca ttgtgcaatt gtgtcttaac 180
ataacttact ttttcttaat aagagaactg gaaataacct cattaggaaa tttagaacaa 240
atabgatgat atctttaaag aaaatggctt tgtgtaagta ttgtcgttag tgatctagta 300
atgtgtatct ttctggttgt atttagacct tcaactcaaa tgtcagctcc cgttaaggtc 360
tatacattgt ggtggttttg tgctgtgggt ccatttagtg atttccctac ctcccatcct 420
ctattagatt cacaactgtt gttctgccca taatttccta tgcttgcttt gcattgttac 480
attttttttt gaaaatcaga aagcaaaatc aatataaagc agccatgtct ggaggagacc 540
aggaggtcaa gaagccttag tttctcaagc ccttagcacc aaattctctg agatcagctc 600
ttccttcagt tacactgagc atttcccctc tgcagtgatg gagaagggag aactcttatt 660
ttttctcatg agcatctctg gggctgtttt ccttagataa ataagtggtt ctatttaatg 720
tgaagcctgt tttatgaaca ggatgaatgt ggtatatatt cagaataact aatgtttgga 780
agttgttttg ttttgctaaa acaaagtttt agcaaacgat tttttttttc aaatttgtgt 840
cttctgttct caaagcatct ctgatgtaag agataatgcg ccacgatggg catcagaaga 900
cctcagctca aatcccagtt ctgccagcta tgagctgtgt ggcaccaaca ggtgtcctgt 960
tctcccaggg tctccctttt cccatttgaa atataaaaaa taacaattcc tgccttcacg 1020
tgttttttta gggggttaaa tggtaaaggt gtttatatct gctaaggtaa tttacttgat 1080
atatgtttgg ttattgaaga t 1101
<210> 4
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(22)
<223>CYP2C19*2 Forward primer sequence
<400> 4
ttgcatattc tgtctgtgcc ag 22
<210> 5
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(22)
<223>CYP2C19*2 Reverse primer sequence
<400> 5
ataaaaacag ctccatgcgg gc 22
<210> 6
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(22)
<223>CYP2C19*3 Forward primer sequence
<400> 6
tctacctgaa gagcaagtcc cc 22
<210> 7
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(22)
<223>CYP2C19*3 Reverse primer sequence
<400> 7
cttccaggag gagttcttga gt 22
<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(22)
<223>CYP2C19*17 Forward primer sequence
<400> 8
aatggggtta gaatccctgt ta 22
<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(22)
<223>CYP2C19*17 Reverse primer sequence
<400> 9
aatagaggat gggaggtagg ga 22

Claims (9)

1. a kind of rapid amplifying kit of CYP2C19 gene, which is characterized in that include that three pairs of amplifications are drawn in the kit Object, Taq enzyme, dNTPs and buffer, wherein amplimer is for expanding CYP2C19*2 type, CYP2C19*3 type and CYP2C19* At least two SNP sites in 17 types, each pair of primer respectively correspond the upstream and downstream region of one of SNP site.
2. the rapid amplifying kit of CYP2C19 gene according to claim 1, it is characterised in that: CYP2C19*2 type Template sequence is expanded as shown in sequence table SEQ ID NO:1, the amplification template sequence of CYP2C19*3 type such as sequence table SEQ ID Shown in NO:2, the amplification template sequence of CYP2C19*17 type is as shown in sequence table SEQ ID NO:3.
3. the rapid amplifying kit of CYP2C19 gene according to claim 1, which is characterized in that three draw primer Object sequence is as shown in sequence table SEQ ID NO:4~SEQ ID NO:9, and wherein SEQ ID NO:4 and SEQ ID NO:5 is respectively The upstream and downstream amplimer of CYP2C19*2 type, SEQ ID NO:6 and SEQ ID NO:7 are respectively the upstream and downstream of CYP2C19*3 type Amplimer, SEQ ID NO:8 and SEQ ID NO:9 are respectively the upstream and downstream amplimer of CYP2C19*17 type.
4. the rapid amplifying kit of CYP2C19 gene according to claim 1, which is characterized in that the amplification system In, the amplimer of each SNP site and the additional amount of template are identical.
5. the rapid amplifying kit of CYP2C19 gene according to claim 1, which is characterized in that the amplifing reagent Box further includes whole blood sample PCR buffer, and the buffer contains 100mmol/L Tris-HCl, 50mmol/L KCl, pH 9.3~9.5.
6. a kind of amplification side of the rapid amplifying kit using CYP2C19 gene as claimed in any one of claims 1 to 5 Method, which is characterized in that the amplification system that the amplification method uses for the PCR system of 25 μ L, specifically:
10×PCR buffer 2μL;
Mg2+(25mmol/L)1μL;
dNTPs(25mmol/L)0.6μL;
Taq enzyme (5U/ μ L) 0.3 μ L;
CYP2C19*2 type, CYP2C19*3 type and/or each 2 μ L of CYP2C19*17 pattern plate;
CYP2C19*2 type, CYP2C19*3 type and/or CYP2C19*17 type upstream and downstream primer (10 μm of ol/L) each 1 μ L;Wherein draw Object is corresponding with the type of template and quantity,
Aseptic double-distilled water polishing is to 25 μ L.
7. the rapid amplifying method of CYP2C19 gene according to claim 6, which is characterized in that the amplification method Reaction condition are as follows: 94 DEG C of initial denaturation 5.5min;Then 94 DEG C of denaturation 30s, 58 DEG C of annealing 45s, 72 DEG C of extension 50s, 36 recycle Afterwards, 72 DEG C of extension 5min again.
8. the rapid amplifying method of CYP2C19 gene according to claim 6, it is characterised in that: for PCR amplification DNA sample is people's whole blood sample after extracting.
9. the rapid amplifying method of CYP2C19 gene according to claim 8, it is characterised in that: when using people's whole blood When product carry out PCR amplification, buffer uses whole blood sample PCR buffer in PCR amplification system.
CN201711267084.5A 2017-12-05 2017-12-05 A kind of the rapid amplifying kit and amplification method of CYP2C19 gene Withdrawn CN109868306A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711267084.5A CN109868306A (en) 2017-12-05 2017-12-05 A kind of the rapid amplifying kit and amplification method of CYP2C19 gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711267084.5A CN109868306A (en) 2017-12-05 2017-12-05 A kind of the rapid amplifying kit and amplification method of CYP2C19 gene

Publications (1)

Publication Number Publication Date
CN109868306A true CN109868306A (en) 2019-06-11

Family

ID=66916423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711267084.5A Withdrawn CN109868306A (en) 2017-12-05 2017-12-05 A kind of the rapid amplifying kit and amplification method of CYP2C19 gene

Country Status (1)

Country Link
CN (1) CN109868306A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111485019A (en) * 2020-04-22 2020-08-04 江苏省人民医院(南京医科大学第一附属医院) Stomach H+/K+Primer, kit and detection method for detecting polymorphism of ATPase gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103184265A (en) * 2011-12-28 2013-07-03 协和干细胞基因工程有限公司 CYP2C19 gene detection kit, amplification method and detection method
CN106222281A (en) * 2016-08-10 2016-12-14 中南大学湘雅三医院 Test kit, application and method of based on the gene pleiomorphism accurate medication of guiding children patient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103184265A (en) * 2011-12-28 2013-07-03 协和干细胞基因工程有限公司 CYP2C19 gene detection kit, amplification method and detection method
CN106222281A (en) * 2016-08-10 2016-12-14 中南大学湘雅三医院 Test kit, application and method of based on the gene pleiomorphism accurate medication of guiding children patient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALICE MATIMBA等: "Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects", 《HUMAN GENOMICS》 *
黄杰等: "CYP2C19基因多态性检测方法的建立", 《药物分析杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111485019A (en) * 2020-04-22 2020-08-04 江苏省人民医院(南京医科大学第一附属医院) Stomach H+/K+Primer, kit and detection method for detecting polymorphism of ATPase gene

Similar Documents

Publication Publication Date Title
Harada et al. Detection of GST1 gene deletion by the polymerase chain reaction and its possible correlation with stomach cancer in Japanese
Sugita et al. Sequence diversity of the intergenic spacer region of the rRNA gene of Malassezia globosa colonizing the skin of patients with atopic dermatitis and healthy individuals
Haas-Rochholz et al. Additional primer sets for an amelogenin gene PCR-based DNA-sex test
CN114686597B (en) SNP molecular marker for sex identification of silver dragon fish and application thereof
KR101564333B1 (en) Single nucleotide polymorphism marker composition for determination of high quality or nutritional value in Hanwoo meat
Linn et al. Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients
KR102313069B1 (en) A new marker for diagnosis of macular degeneration and a diagnostic method using the same
CN102776286A (en) Primer, probe and assay kit for detecting v-ros avian UR2 sarcoma viral oncogene homolog 1 (ROS1) gene fusion mutation
KR20240137535A (en) Analytical methods for providing an informationn necessary for diagnosing colorectal cancer
KR100804310B1 (en) 4 DNA marker of adipocyte-fatty acid binding protein gene related the intramuscular fat content in beef cattle
CN109868306A (en) A kind of the rapid amplifying kit and amplification method of CYP2C19 gene
Shayan et al. Innovative restriction site created PCR-RFLP for detection of benzimidazole resistance in Teladorsagia circumcincta
KR102368835B1 (en) Primer sets for determining genotype of HSPB1 gene related to meat of Korean native cattle and uses thereof
Lohar Textbook of Biotechnology
Franco et al. Molecular bases of the ABO blood groups of Indians from the Brazilian Amazon region
Roudknar et al. Detection of Rare and Unknown Mutations in ß-tathalassemia Traits in Iran
CN106498073A (en) A kind of SNP marker related to Xinjiang Donkey milk production trait and its application
Köseler et al. Molecular identification of a rare hemoglobin variant, Hb J-Iran [beta77 (EF1) His-> Asp], in Denizli province of Turkey
Zhang et al. On/off switch mediated by exo+ polymerases: Experimental analysis for its physiological and technological implications
JP2021122180A (en) Quantitative method of disease dna
Fejes-Tóth et al. Intrarenal distribution of the colonic H, K-ATPase mRNA in rabbit
KR101728421B1 (en) Markers for identitying fish species contained in surimi products
AL-BARZINJI et al. Specific genes affecting body weight in Iraqi Awassi sheep
CN105316393A (en) Rapid detection method for detecting deletion mutation of cell apoptosis regulator gene (BIM) and detection kit thereof
KR101787260B1 (en) A kit and the method for determining seed bulls

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20190611